218 related articles for article (PubMed ID: 22156471)
1. Histone deacetylase inhibition decreases proliferation and potentiates the effect of ionizing radiation in atypical teratoid/rhabdoid tumor cells.
Knipstein JA; Birks DK; Donson AM; Alimova I; Foreman NK; Vibhakar R
Neuro Oncol; 2012 Feb; 14(2):175-83. PubMed ID: 22156471
[TBL] [Abstract][Full Text] [Related]
2. Targeting the TP53/MDM2 axis enhances radiation sensitivity in atypical teratoid rhabdoid tumors.
Alimova I; Wang D; Danis E; Pierce A; Donson A; Serkova N; Madhavan K; Lakshmanachetty S; Balakrishnan I; Foreman NK; Mitra S; Venkataraman S; Vibhakar R
Int J Oncol; 2022 Mar; 60(3):. PubMed ID: 35179215
[TBL] [Abstract][Full Text] [Related]
3. Histone deacetylase inhibitors induce cell death and enhance the susceptibility to ionizing radiation, etoposide, and TRAIL in medulloblastoma cells.
Sonnemann J; Kumar KS; Heesch S; Müller C; Hartwig C; Maass M; Bader P; Beck JF
Int J Oncol; 2006 Mar; 28(3):755-66. PubMed ID: 16465382
[TBL] [Abstract][Full Text] [Related]
4. Sensitization to gamma-irradiation-induced cell cycle arrest and apoptosis by the histone deacetylase inhibitor trichostatin A in non-small cell lung cancer (NSCLC) cells.
Zhang F; Zhang T; Teng ZH; Zhang R; Wang JB; Mei QB
Cancer Biol Ther; 2009 May; 8(9):823-31. PubMed ID: 19270532
[TBL] [Abstract][Full Text] [Related]
5. Histone deacetylase inhibitors sensitize human non-small cell lung cancer cells to ionizing radiation through acetyl p53-mediated c-myc down-regulation.
Seo SK; Jin HO; Woo SH; Kim YS; An S; Lee JH; Hong SI; Lee KH; Choe TB; Park IC
J Thorac Oncol; 2011 Aug; 6(8):1313-9. PubMed ID: 21642861
[TBL] [Abstract][Full Text] [Related]
6. Inhibitors of histone deacetylases as potential therapeutic tools for high-risk embryonal tumors of the nervous system of childhood.
Furchert SE; Lanvers-Kaminsky C; Juürgens H; Jung M; Loidl A; Frühwald MC
Int J Cancer; 2007 Apr; 120(8):1787-94. PubMed ID: 17230517
[TBL] [Abstract][Full Text] [Related]
7. In Vitro Investigation Demonstrates IGFR/VEGFR Receptor Cross Talk and Potential of Combined Inhibition in Pediatric Central Nervous System Atypical Teratoid Rhabdoid Tumors.
Obaid H; Kannappan S; Gupta M; Ruan Y; Zhang C; Bose P; Narendran A
Curr Cancer Drug Targets; 2020; 20(4):295-305. PubMed ID: 31713485
[TBL] [Abstract][Full Text] [Related]
8. Profiling pathway-specific novel therapeutics in preclinical assessment for central nervous system atypical teratoid rhabdoid tumors (CNS ATRT): favorable activity of targeting EGFR- ErbB2 signaling with lapatinib.
Singh A; Lun X; Jayanthan A; Obaid H; Ruan Y; Strother D; Chi SN; Smith A; Forsyth P; Narendran A
Mol Oncol; 2013 Jun; 7(3):497-512. PubMed ID: 23375777
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of EZH2 suppresses self-renewal and induces radiation sensitivity in atypical rhabdoid teratoid tumor cells.
Alimova I; Birks DK; Harris PS; Knipstein JA; Venkataraman S; Marquez VE; Foreman NK; Vibhakar R
Neuro Oncol; 2013 Feb; 15(2):149-60. PubMed ID: 23190500
[TBL] [Abstract][Full Text] [Related]
10. Resveratrol-induced apoptosis and increased radiosensitivity in CD133-positive cells derived from atypical teratoid/rhabdoid tumor.
Kao CL; Huang PI; Tsai PH; Tsai ML; Lo JF; Lee YY; Chen YJ; Chen YW; Chiou SH
Int J Radiat Oncol Biol Phys; 2009 May; 74(1):219-28. PubMed ID: 19362240
[TBL] [Abstract][Full Text] [Related]
11. Targeting of RRM2 suppresses DNA damage response and activates apoptosis in atypical teratoid rhabdoid tumor.
Giang LH; Wu KS; Lee WC; Chu SS; Do AD; Changou CA; Tran HM; Hsieh TH; Chen HH; Hsieh CL; Sung SY; Yu AL; Yen Y; Wong TT; Chang CC
J Exp Clin Cancer Res; 2023 Dec; 42(1):346. PubMed ID: 38124207
[TBL] [Abstract][Full Text] [Related]
12. Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci.
Munshi A; Tanaka T; Hobbs ML; Tucker SL; Richon VM; Meyn RE
Mol Cancer Ther; 2006 Aug; 5(8):1967-74. PubMed ID: 16928817
[TBL] [Abstract][Full Text] [Related]
13. Low-Dose Histone Deacetylase Inhibitor Treatment Leads to Tumor Growth Arrest and Multi-Lineage Differentiation of Malignant Rhabdoid Tumors.
Muscat A; Popovski D; Jayasekara WS; Rossello FJ; Ferguson M; Marini KD; Alamgeer M; Algar EM; Downie P; Watkins DN; Cain JE; Ashley DM
Clin Cancer Res; 2016 Jul; 22(14):3560-70. PubMed ID: 26920892
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of DNA damage repair by the CDK4/6 inhibitor palbociclib delays irradiated intracranial atypical teratoid rhabdoid tumor and glioblastoma xenograft regrowth.
Hashizume R; Zhang A; Mueller S; Prados MD; Lulla RR; Goldman S; Saratsis AM; Mazar AP; Stegh AH; Cheng SY; Horbinski C; Haas-Kogan DA; Sarkaria JN; Waldman T; James CD
Neuro Oncol; 2016 Nov; 18(11):1519-1528. PubMed ID: 27370397
[TBL] [Abstract][Full Text] [Related]
15. Functional relevance of genes predicted to be affected by epigenetic alterations in atypical teratoid/rhabdoid tumors.
Tegeder I; Thiel K; Erkek S; Johann PD; Berlandi J; Thatikonda V; Frühwald MC; Kool M; Jeibmann A; Hasselblatt M
J Neurooncol; 2019 Jan; 141(1):43-55. PubMed ID: 30446899
[TBL] [Abstract][Full Text] [Related]
16. Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101.
Duan J; Friedman J; Nottingham L; Chen Z; Ara G; Van Waes C
Mol Cancer Ther; 2007 Jan; 6(1):37-50. PubMed ID: 17237265
[TBL] [Abstract][Full Text] [Related]
17. Targeting Aurora Kinase A enhances radiation sensitivity of atypical teratoid rhabdoid tumor cells.
Venkataraman S; Alimova I; Tello T; Harris PS; Knipstein JA; Donson AM; Foreman NK; Liu AK; Vibhakar R
J Neurooncol; 2012 May; 107(3):517-26. PubMed ID: 22246202
[TBL] [Abstract][Full Text] [Related]
18. Atypical teratoid/rhabdoid tumors (ATRT): improved survival in children 3 years of age and older with radiation therapy and high-dose alkylator-based chemotherapy.
Tekautz TM; Fuller CE; Blaney S; Fouladi M; Broniscer A; Merchant TE; Krasin M; Dalton J; Hale G; Kun LE; Wallace D; Gilbertson RJ; Gajjar A
J Clin Oncol; 2005 Mar; 23(7):1491-9. PubMed ID: 15735125
[TBL] [Abstract][Full Text] [Related]
19. In vivo efficacy of the histone deacetylase inhibitor suberoylanilide hydroxamic acid in combination with radiotherapy in a malignant rhabdoid tumor mouse model.
Thiemann M; Oertel S; Ehemann V; Weichert W; Stenzinger A; Bischof M; Weber KJ; Perez RL; Haberkorn U; Kulozik AE; Debus J; Huber PE; Battmann C
Radiat Oncol; 2012 Mar; 7():52. PubMed ID: 22458853
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase inhibitors induce cell death and enhance the apoptosis-inducing activity of TRAIL in Ewing's sarcoma cells.
Sonnemann J; Dreyer L; Hartwig M; Palani CD; Hong le TT; Klier U; Bröker B; Völker U; Beck JF
J Cancer Res Clin Oncol; 2007 Nov; 133(11):847-58. PubMed ID: 17486365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
